Issue 19 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

33

No.

19

May 18, 2007May 18, 2007

Free

DOWNLOAD THE PDF

After ODAC: Questions On ESA Claims, Advertising, Reimbursement Gain Urgency.

Amgen Claimed QOL Benefit Despite FDA Label Change.

“Miracle-Gro for Cancer?” ODAC Members Vent At Amgen And J&J Over Claims, Advertising.

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

CMS Proposal To Limit ESA Use Is Too Much, Too Fast, Critics Say.

Recent Issues

Volume 51 | Issue 27 - July 11, 2025

Volume 51 | Issue 26 - July 03, 2025

Volume 51 | Issue 25 - June 27, 2025

Volume 51 | Issue 24 - June 20, 2025

Volume 51 | Issue 23 - June 13, 2025

Volume 51 | Issue 22 - June 06, 2025